Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Find information and resources for current and returning patients.
Learn about clinical trials at MD Anderson and search our database for open studies.
The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.
Your gift will help support our mission to end cancer and make a difference in the lives of our patients.
Our personalized portal helps you refer your patients and communicate with their MD Anderson care team.
As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.
Choose from 12 allied health programs at School of Health Professions.
View open postdoctoral and other research trainee positions.
Learn about our graduate medical education residency and fellowship opportunities.
Study finds anti-tumor activity improved by engineering CAR NK cells with IL-15, conducting multiple infusions
MD Anderson News Release July 26, 2023
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.
The study, published today in Science Advances, demonstrates that engineering CAR NK cells to express interleukin-15 (IL-15) enhances the cells’ metabolic fitness and provides a longer-lasting anti-tumor response. In addition, two infusions of CAR NK cells expressing IL-15 boosted survival in comparison to a single dose.
The collaborative research was led by co-corresponding authors Ken Chen, Ph.D., professor of Bioinformatics and Computational Biology, and Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy, along with researchers in the Chen and Rezvani labs.
“Understanding the mechanism of resistance facilitates more focused interrogation to identify strategies by which we can mitigate or circumvent these resistance mechanisms and improve efficacy of the CAR NK cell therapy,” Chen said.
As part of the preclinical study, researchers focused on genetically engineered NK cells with a CAR targeting the CD19 tumor antigen (CAR19). Using laboratory models of lymphoma, they evaluated cells that expressed either CAR19 alone, IL-15 alone, or both CAR19 and IL-15 to investigate the ability of IL-15 to activate NK cells and to enhance their potency and persistence.
Researchers observed the emergence of NK cell clusters with distinct patterns of activation, function and metabolic signature associated with different phases of in vivo evolution and tumor control. Interactions with the highly metabolically active tumor resulted in loss of metabolic fitness in NK cells that was partly overcome with the expression of IL-15.
To overcome this resistance, mice received a second infusion of CAR19/IL-15 NK cells 14 days after the first. The second infusion increased the number of functional NK cells and resulted in long-term tumor eradication.
The relevance of the preclinical findings were confirmed in samples from two patients with lymphoid malignancies treated with CAR19/IL-15 NK cells as part of a recent clinical trial.
“Our data suggest that successful treatment using CAR NK cells may require multiple infusions in order to achieve a robust NK cell population capable of mounting a strong anti-tumor response, especially for difficult to treat and highly metabolically active tumors,” Rezvani said.
The increase in functional NK cells with a second infusion provides researchers with a clinically actionable strategy to improve efficacy of CAR NK cell therapy and warrants further investigation. Researchers will continue to validate their findings in additional tumor models and study mechanisms of resistance in upcoming clinical trials with CAR NK cells targeting CD70 in solid tumors.
A full list of collaborating authors and their disclosures can be found with the full paper here. The research was supported in part by MD Anderson’s Moon Shots Program® and its adoptive cell therapy platform. Additional support includes the Sally Cooper Murray Chair in Cancer Research, the National Institutes of Health (1 R01 CA211044-01, 5 P01CA148600-03, U01CA247760, P50CA100632, P30CA016672), the Cancer Prevention and Research Institute of Texas (RP180466, RP180248), and the Chan Zuckerberg Initiative.
© 2023 The University of Texas MD Anderson Cancer Center